Development and application of vaccines against echinococcosis
ZHANG Wen-bao1, ZHANG Zhuang-zhi2, ZHENG Xue-ting1, LI Jun1
1. State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medicine Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China; 2. Xinjiang Academy of Animal Sciences, Veterinary Institute, Urumqi 830011,China
Abstract:Control of echinococcosis (hydatid disease)is a long and complicated task. Before 1990’s, chemotherapy played an important role in control and treatment of helminth diseases. However, since then, vaccine development against helminth diseases has been paid more attention due simply to the risk of drug resistance, less efficacy of control progress and environment impact by largely using drugs. This review summarizes the development of vaccines against the larval and adult stages of Echinococcus. The subunit vaccine EG95 has been successfully developed and been widely used as a control measure in western China. However, given that the lifecycle of Echinococcus multilocularis is maintained in wild animals (sylvatic lifecycle) including small mammals(usually microtine and arvicolid rodents)act as intermediate hosts and dogs/foxes as definitive hosts, a vaccine against the adult worms in the definitive hosts may be one of solution for control of alveolar echinococcosis.
张文宝, 张壮志, 郑雪婷, 李军. 棘球蚴(包虫)病预防疫苗的研制与应用[J]. 中国人兽共患病学报, 2018, 34(9): 834-838.
ZHANG Wen-bao, ZHANG Zhuang-zhi, ZHENG Xue-ting, LI Jun. Development and application of vaccines against echinococcosis. Chinese Journal of Zoonoses, 2018, 34(9): 834-838.
[1] Gemmell M A, Roberts M G, Beard T C, et al.Control of echinococcosis[J]. Bulletin of the World Health Organization, 1986, 64(3):333-9. [2] Craig P S, Mcmanus D P, Lightowlers M W, et al.Prevention and control of cystic echinococcosis[J]. Lancet Infect Dis, 2007, 7(6):385-94. DOI: 10.1016/S1473-3099(07)70134-2 [3] Zhang W, Mcmanus D P.Vaccination of dogs against Echinococcus granulosus: a means to control hydatid disease?[J]. Trends Parasitol, 2008, 24(9):419. DOI: 10.1016/j.pt.2008.05.008 [4] Thompson R C.Biology and Systematics of Echinococcus[J]. Adv Parasitol, 2016, 95:65-109. DOI: 10.1016/bs.apar.2016.07.001 [5] Zheng H, Zhang W, Zhang L, et al.The genome of the hydatid tapeworm Echinococcus granulosus[J]. Nat Genet, 2013, 45(10):1168-1175. DOI: 10.1038/ng.2757 [6] Johnson K S, Harrison G B, Lightowlers M W, et al.Vaccination against ovine cysticercosis using a defined recombinant antigen[J]. Nature, 1989, 338(6216):585-587. [7] Lightowlers M W.Australasian contributions to anti-parasite vaccines[J]. Int J Parasitol, 1997, 27(10): 1121-5. [8] Rickard MD. Cestode vaccines[J]. Southeast Asian J Trop Med Public Health 1991, 22 Suppl(22 Suppl):287-290. [9] Gemmell MA.Immunological responses of the mammalian host against tapeworm infections. IV. Species specificity of hexacanth embryos in protecting sheep against Echinococcus granulosus[J]. Immunology, 1966, 11(4):325-35. [10] Heath DD, Lawrence SB.Antigenic polypeptides of Echinococcus granulosus oncospheres and definition of protective molecules[J]. Parasite Immunol, 1996, 18(7): 347-57. [11] Lightowlers MW, Lawrence SB, Gauci CG, et al.Vaccination against hydatidosis using a defined recombinant antigen[J]. Parasite Immunol, 1996, 18(9): 457-62. [12] Gauci C, Heath D, Chow C, et al.Hydatid disease: vaccinology and development of the EG95 recombinant vaccine[J]. Expert Rev Vaccines, 2005, 4(1): 103-12. DOI: 10.1586/14760584.4.1.103 [13] Lightowlers MW, Heath DD.Immunity and vaccine control of Echinococcus granulosus infection in animal intermediate hosts[J]. Parassitologia, 2004, 46(1-2):27-31. [14] Barnes TS, Hinds LA, Jenkins DJ, et al.Efficacy of the EG95 hydatid vaccine in a macropodid host, the tammar wallaby[J]. Parasitology, 2009, 136(4):461-468. DOI: 10.1017/S0031182009005526 [15] Lightowlers MW, Gauci CG, Chow C, et al.Molecular and genetic characterisation of the host-protective oncosphere antigens of taeniid cestode parasites[J]. Int J Parasitol, 2003, 33(11): 1207-17. [16] Gauci C, Merli M, Muller V, et al.Molecular cloning of a vaccine antigen against infection with the larval stage of Echinococcus multilocularis[J]. Infect Immun, 2002, 70(7): 3969-72. [17] Zhang W, Zhang Z, Yimit T, et al.A Pilot Study for Control of Hyperendemic Cystic Hydatid Disease in China[J]. PLoS Negl Trop Dis, 2009, 3(10):e534. DOI: 10.1371/journal.pntd.0000534 [18] Torgerson P R.Canid immunity to Echinococcus spp.: impact on transmission[J]. Parasite Immunol, 2006, 28(7): 295-303.DOI: 10.1111/j.1365-3024.2006.00819.x [19] Zhang W, Li J, You H, et al.A gene family from Echinococcus granulosus differentially expressed in mature adult worms[J]. Mol Biochem Parasitol, 2003, 126(1): 25-33. [20] Zhang W, Zhang Z, Shi B, et al.Vaccination of Dogs against Echinococcus granulosus, the Cause of Cystic Hydatid Disease in Humans[J]. J Infect Dis, 2006, 194(7): 966-74. DOI: 10.1086/506622 [21] Chabalgoity J A, Moreno M, Carol H, et al.Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine[J]. Vaccine, 2000, 19(4-5): 460-9. [22] Gottstein B, Müller N, Jr S J C, et al. Humoral and cellular immune response in mice and dogs induced by a recombinant Echinococcus multilocularis antigen produced by a Salmonella typhimurium vaccine strain[J]. Parasite Immunol, 1990, 12(2): 163-74. [23] Petavy A F, Hormaeche C, Lahmar S, et al.An Oral Recombinant Vaccine in Dogs against Echinococcus granulosus, the Causative Agent of Human Hydatid Disease: A Pilot Study[J]. PLoS Negl Trop Dis, 2008, 2(1): e125. DOI: 10.1371/journal.pntd.0000125 [24] Barriga O O, Al-khalidi N W. Humoral immunity in the prepatent primary infection of dogs with Echinococcus granulosus.[J]. Vet Immunol Immunopathol, 1986, 11(4): 375-89. [25] Carmena D, Benito A, Martinez J, et al.Preliminary study of the presence of antibodies against excretory-secretory antigens from protoscoleces of Echinococcus granulosus in dogs with intestinal echinococcosis[J]. Mem Inst Oswaldo Cruz, 2005, 100(3): 311-7. DOI: /S0074-02762005000300018 [26] Moreno M, Benavidez U, Carol H, et al.Local and systemic immune responses to Echinococcus granulosus in experimentally infected dogs[J]. Vet Parasitol, 2004, 119(1): 37-50. DOI: 10.1016/j.vetpar.2003.10.020 [27] Herd R P, KO L, Weisbrode S E, et al.Sequential morphologic changes in adult Echinococcus granulosus during complement-mediated lysis in vitro[J]. Int J Parasitol, 1984, 14(2): 141-9. [28] Herd R P.The cestocidal effect of complement in normal and immune sera in vitro[J]. Parasitology, 1976, 72(325-34). [29] Carol H, Nieto A.A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms[J]. Vet Immunol Immunopathol, 1998, 65(1): 29-41. [30] Tsai I J, Zarowiecki M, Holroyd N, et al.The genomes of four tapeworm species reveal adaptations to parasitism[J]. Nature, 2013, 496(7443):57-63. DOI: 10.1038/nature12031 [31] Gemmell M A, Lawson J R, Roberts M G.Population dynamics in echinococcosis and cysticercosis: biological parameters of Echinococcus granulosus in dogs and sheep[J]. Parasitology, 1986, 92(Pt 3): 599-620. [32] Rossi A, Marques J M, Gavidia C M, et al.Echinococcus granulosus: different cytokine profiles are induced by single versus multiple experimental infections in dogs[J]. Exp Parasitol, 2012, 130(2): 110-5. DOI: 10.1016/j.exppara.2011.12.006